Evidence map›Paper›PMID 42011461›Full record

ArticleCureus2026

Double Trouble: EPCAM Exon 9 Deletion in Lynch Syndrome Leading to Dual Primary Tumors.

Areti Kalfoutzou, Cleopatra Rapti, Zannis Almpanis, Eleftheria Bagiokou, Nikolaos Kalakos, Vasiliki Lagopoulou, Vasileios Kolintzikis, Aristeidis Oikonomakis, Nikolaos Chaleplidis, Vasileios Ramfidis

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Areti KalfoutzouDepartment of Medical Oncology, 251 Air Force General Hospital, Athens, GRC.
Cleopatra RaptiDepartment of Medical Oncology, 251 Air Force General Hospital, Athens, GRC.
Zannis AlmpanisDepartment of Pathology, Pathlabs - Pathology Laboratory of Athens, Athens, GRC.
Eleftheria BagiokouDepartment of Medical Oncology, 251 Air Force General Hospital, Athens, GRC.
Nikolaos KalakosDepartment of Gastroenterology, General Hospital of Athens "G. Gennimatas", Athens, GRC.
Vasiliki LagopoulouDepartment of Pathology, 251 Air Force General Hospital, Athens, GRC.
Vasileios KolintzikisSecond Department of Medical Oncology, Agios Savvas Cancer Hospital, Athens, GRC.
Aristeidis OikonomakisDepartment of Gastroenterology, 251 Air Force General Hospital, Athens, GRC.
Nikolaos ChaleplidisDepartment of Pathology, 251 Air Force General Hospital, Athens, GRC.
Vasileios RamfidisDepartment of Medical Oncology, 251 Air Force General Hospital, Athens, GRC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lynch syndrome (LS) is one of the most widely recognized cancer susceptibility syndromes and is caused by germline mutations of the mismatch repair (MMR) genes

Indexed as

dna mismatch repairgene deletionimmunotherapylynch syndromemsh2 protein

Identifiers

PMID42011461
PMCPMC13091914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.